ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work
in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary
peritoneal cancer that has come back (recurrent), or that does not respond to treatment
(refractory). ONC201 is the first in its class of drugs that antagonize some specific cell
receptors on cancer cells, leading to their destruction. Drugs used in chemotherapy, such as
paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving ONC201 and
paclitaxel may work better in treating patients with platinum-resistant epithelial ovarian,
fallopian tube, or primary peritoneal cancer compared to paclitaxel alone.